🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  2. Pelareorep

    ONCOLYTICS BIOTECH INC

    Anatomic Stage IV Breast Cancer AJCC v8

    phase 2 mab active

    1 trial

  3. Pembrolizumab

    IO Biotech

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Pembrolizumab

    Inhibrx Biosciences

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Pembrolizumab (KEYTRUDA®) and PDS0101

    PDS Biotechnology Corp

    Metastatic Head and Neck Cancer

    phase 2 other completed

    1 trial

  6. Pemetrexed

    Mereo BioPharma Group plc

    Nonsquamous Nonsmall Cell Neoplasm of Lung

    phase 2 small molecule completed

    1 trial

  7. Pemetrexed

    Samsung Bioepis NL B.V.

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  8. Pemetrexed and Reolysin (and safety run-in)

    ONCOLYTICS BIOTECH INC

    Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  9. Pemoline

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    2 trials

  10. Pepinemab

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  11. Peramivir

    Biocryst

    Acute, Uncomplicated Human Influenza

    phase 2 small molecule completed

    1 trial

  12. Peramivir 150 mg

    Biocryst

    Influenza

    phase 2 small molecule completed

    1 trial

  13. Peramivir 200 mg

    Biocryst

    Influenza

    phase 2 small molecule completed

    1 trial

  14. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  15. Phage Therapy

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 mab terminated

    2 trials

  16. Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

    The George Institute

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  17. Phase 2, Open label Study of Patritumab Deruxtecan (U3-1402), an Anti-HER3-Antibody Drug Conjugate (ADC), in patients with Advanced Breast Cancer, with biomarker analyses to characterize response to therapy

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  18. Phenoptin

    BioMarin Pharmaceutical Australia Pty Ltd

    Tetrahydrobiopterin Deficiencies

    phase 2 small molecule completed

    1 trial

  19. Piclidenoson

    Can-Fite BioPharma

    COVID-19

    phase 2 small molecule completed

    1 trial

  20. Piclidenoson

    Can-Fite BioPharma

    Lowe Syndrome

    phase 2 small molecule active

    1 trial

  21. Pioglitazone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    1 trial

  22. Pitolisant Oral Tablet

    Harmony Biosciences Holdings

    Myotonic Dystrophy 1

    phase 2 small molecule completed

    1 trial

  23. Pitolisant oral tablets

    Harmony Biosciences Holdings

    Prader-Willi Syndrome

    phase 2 small molecule completed

    1 trial

  24. Placebo

    Biotech Pharmaceutical Co.,

    Hemophilic Arthropathy

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources